March 21 (Reuters) - Embattled Canadian drugmaker Valeant
Pharmaceuticals International Inc VRX.N VRX.TO said on
Monday Chief Executive Michael Pearson (LON:PSON) would step down and that
the company had appointed activist investor William Ackman to
its board.
The company said it had started a search for a successor to
Pearson.